



COPY OF PAPERS  
ORIGINALLY FILED

Attorney's Docket

0287-051002 / MON 1470.2

Election/Amendment B/#10  
6/24/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael Detmar et al.

Art Unit : 1642

Serial No. : 09/822,682

Examiner : N. Davis

Filed : March 30, 2001

Title : THROMBOSPONDIN-2 AND USES THEREOF

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
JUN 19 2002  
TECH CENTER 1600/2900

PRELIMINARY AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Prior to substantive examination, please amend the application as follows.

In the claims:

Cancel claims 1-53 without prejudice or disclaimer.

Amend claims 54 and 55 as follows.

B1  
Amend  
C2

54. (Amended) A method of treating a subject having a disorder characterized by unwanted cell proliferation, the method comprising:  
identifying a subject having a disorder characterized by unwanted cell proliferation; and  
administering to the subject a cell expressing TSP-2 or a functional fragment or analog thereof.

55. (Amended) The method of claim 54, wherein the cell is a genetically engineered cell modified to cause the expression of TSP-2 or a functional fragment or analog thereof.

Add new claims 56-80.

56. The method of claim 55, wherein the cell has been genetically modified to introduce a regulatory sequence that causes or increases the expression of an endogenous TSP-2 gene.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

June 6, 2002  
Date of Deposit

Signature

Typewritten or Printed Name of Person Signing Certificate